JP2005523730A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523730A5
JP2005523730A5 JP2004514868A JP2004514868A JP2005523730A5 JP 2005523730 A5 JP2005523730 A5 JP 2005523730A5 JP 2004514868 A JP2004514868 A JP 2004514868A JP 2004514868 A JP2004514868 A JP 2004514868A JP 2005523730 A5 JP2005523730 A5 JP 2005523730A5
Authority
JP
Japan
Prior art keywords
serotype
adenovirus
cells
cell line
subgroup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004514868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523730A (ja
JP4495588B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/050126 external-priority patent/WO2004001032A2/en
Publication of JP2005523730A publication Critical patent/JP2005523730A/ja
Publication of JP2005523730A5 publication Critical patent/JP2005523730A5/ja
Application granted granted Critical
Publication of JP4495588B2 publication Critical patent/JP4495588B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004514868A 2002-04-25 2003-04-24 安定なアデノウイルスベクターおよびその増殖方法 Expired - Lifetime JP4495588B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL0200281 2002-04-25
NL0200656 2002-10-15
EP02102631 2002-11-25
PCT/EP2003/050126 WO2004001032A2 (en) 2002-04-25 2003-04-24 Stable adenoviral vectors and methods for propagation thereof

Publications (3)

Publication Number Publication Date
JP2005523730A JP2005523730A (ja) 2005-08-11
JP2005523730A5 true JP2005523730A5 (https=) 2010-05-06
JP4495588B2 JP4495588B2 (ja) 2010-07-07

Family

ID=34068720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004514868A Expired - Lifetime JP4495588B2 (ja) 2002-04-25 2003-04-24 安定なアデノウイルスベクターおよびその増殖方法

Country Status (17)

Country Link
US (2) US7285265B2 (https=)
EP (1) EP1497440B1 (https=)
JP (1) JP4495588B2 (https=)
KR (1) KR101006594B1 (https=)
CN (1) CN100374574C (https=)
AT (1) ATE405663T1 (https=)
AU (1) AU2003271738C1 (https=)
CA (1) CA2478508C (https=)
DE (1) DE60323080D1 (https=)
DK (1) DK1497440T3 (https=)
ES (1) ES2310247T3 (https=)
IL (1) IL164802A0 (https=)
NO (1) NO334299B1 (https=)
NZ (1) NZ534865A (https=)
PL (1) PL208588B1 (https=)
SI (1) SI1497440T1 (https=)
WO (1) WO2004001032A2 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2003104467A1 (en) * 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
JP5213298B2 (ja) 2002-05-27 2013-06-19 ホルム，ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
US20040106194A1 (en) * 2002-08-22 2004-06-03 Bett Andrew J. Methods for propagating adenovirus and virus produced thereby
US20050036989A1 (en) * 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CN102220357B (zh) 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
SG158133A1 (en) 2004-12-31 2010-01-29 Sonne Holm Method for reversing multiple resistance in animal cells
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
JP2008541730A (ja) * 2005-05-23 2008-11-27 ヴァクシン インコーポレイテッド 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
NZ602504A (en) 2008-11-18 2014-01-31 Beth Israel Hospital Antiviral vaccines with improved cellular immunogenicity
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
DK2655604T3 (en) 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
EP3566714A1 (en) 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
EP2870236B1 (en) * 2012-07-04 2018-01-10 Sirion Biotech GmbH Means and methods to increase adenovirus production
US10106781B2 (en) * 2012-11-16 2018-10-23 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CA2960096A1 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
PT3188753T (pt) 2014-09-03 2020-03-25 Bavarian Nordic As Métodos e composições para induzir imunidade protetora contra infeção por filovírus
CN106999571B (zh) 2014-09-26 2020-10-02 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
TWI710635B (zh) * 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
BE1023877B1 (fr) 2015-05-21 2017-09-01 Glaxosmithkline Biologicals Sa Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
DK3584252T3 (da) 2015-12-15 2021-11-15 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200015759A (ko) 2017-06-15 2020-02-12 얀센 백신스 앤드 프리벤션 비.브이. Hiv 항원을 인코딩하는 폭스바이러스 벡터, 및 그 사용 방법
CN111163799A (zh) 2017-07-28 2020-05-15 扬森疫苗与预防公司 用于异源repRNA免疫接种的方法和组合物
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
US11773142B2 (en) 2017-12-11 2023-10-03 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
KR20200100745A (ko) 2017-12-19 2020-08-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
WO2020229577A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
JP2022532742A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
IL299571A (en) 2020-07-08 2023-02-01 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN117821405B (zh) * 2023-11-24 2024-11-26 广州医科大学 基因嵌合型人腺病毒及其构建方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
WO1998050053A1 (en) 1997-05-08 1998-11-12 Genetic Therapy, Inc. Gene transfer with adenoviruses having modified fiber proteins
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU776067B2 (en) 1999-03-04 2004-08-26 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
ES2372823T3 (es) * 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6365394B1 (en) * 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
DE10045687B4 (de) * 2000-09-15 2006-07-06 MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald Expressionskassetten und Adenovirusvektoren
CA2421864A1 (en) 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie

Similar Documents

Publication Publication Date Title
JP2005523730A5 (https=)
Gao et al. State‐of‐the‐art human adenovirus vectorology for therapeutic approaches
Trowitzsch et al. New baculovirus expression tools for recombinant protein complex production
Ansorge et al. Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
Vogels et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity
EP0705344B1 (en) Adenovirus vectors for gene therapy
Mizuguchi et al. Approaches for generating recombinant adenovirus vectors
Mizuguchi et al. CAR-or αv integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice
CA2428739A1 (en) Complementing cell lines
JP2003514526A5 (https=)
JP5986381B2 (ja) ベクター
CN110892064A (zh) 腺病毒载体
Ostapchuk et al. Characterization of empty adenovirus particles assembled in the absence of a functional adenovirus IVa2 protein
EP0809704B1 (fr) Procede de preparation de genome d'adenovirus recombinants
François et al. Construction of avian adenovirus CELO recombinants in cosmids
Choi et al. AdHTS: a high-throughput system for generating recombinant adenoviruses
WO1996025506A9 (fr) Procede de preparation de genome d'adenovirus recombinants
Doerfler A new concept in (adenoviral) oncogenesis: integration of foreign DNA and its consequences
Carina Silva et al. Adenovirus vector production and purification
Khatri et al. Gene Expression by Atypical Recombinant Ovine Adenovirus Vectors during Abortive Infection of Human and Animal Cellsin Vitro
Zhou et al. Vaccine design: replication-defective adenovirus vectors
Lan et al. Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines
JP2007507216A5 (https=)
Wang et al. Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression